Explore EXEL's revenue growth through cabozantinib, mixed trial updates on zanzalintinib, and potential market shifts ...

We recently compiled a list of 11 Best Future Stocks to Buy Now. CG Oncology, Inc. stands sixth on our list. CG Oncology, Inc ...

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its ...

They evaluated pembrolizumab in patients with resectable stage II-IV (M0) cSCC. Patients received 200 mg pembrolizumab every 3 weeks for 4 cycles, followed by 18F-labeled fluorodeoxyglucose-positron ...

These data support the use of sacituzumab plus pembrolizumab as a potential new standard of care,” said Sara Tolaney, MD.

Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next ...

Beyond healthcare OneMedNet’s proprietary AI anonymizes data for industries like finance, retail, and telecom, unlocking ...

GSK’s anti-TIM monoclonal antibody (mAb) cobolimab has failed a Phase III trial in non-small cell lung cancer (NSCLC). The ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

Investing.com -- OneMedNet Corporation (NASDAQ: ONMD) stock gained 6% premarket after announcing a partnership with Inka Health Corp., a subsidiary of Onco-Innovations Limited (CBOE CA:ONCO), to ...

Merck & Co – known as MSD outside of the US and Canada – has unveiled a new cost-cutting plan aimed at saving $3bn every year by the end of 2027.